Biostatistics is the application of statistical principles and methods to medical and health-related questions. In clinical trials, it translates the scientific question into a robust study design, pre-specified analyses and traceable conclusions about the benefits and risks of a treatment.<\/p>\n
Biostatistics begins before the inclusion of the first trial participants. It helps to define the target population, comparator group, endpoints, randomization and handling of confounding variables in such a way that the intended treatment effect can be estimated as unbiasedly and precisely as possible. A control group should allow to identify which proportion of an observed outcome is due to the investigational treatment and which to the disease course, expectations or other influences. Randomization and, as far as possible, blinding are essential tools for limiting such biases.<\/p>\n
The statistical concept includes the study hypotheses, choice of analysis populations, sample size justification as well as rules for interim analyses and the handling of missing data. These elements do not stand in isolation. A primary endpoint, for instance, requires a clinically meaningful definition, an analysis method, an assumption about the expected information and a sample size matching the question. Responsibility for statistical work should lie with qualified and experienced statisticians.<\/p>\n
According to ICH E9(R1), a study objective is first translated into a precise clinical question and an estimand. The estimand describes the treatment effect that is to be estimated; it defines, among other things, the population, variable, comparison and handling of events after the start of treatment that may influence interpretation. Only then are an estimator, i.e. the analysis method, and a sensitivity analysis determined. This prevents the method from subsequently determining the clinical question.<\/p>\n
The statistical analysis plan specifies the pre-defined details. It describes, for example, models, analysis time points, covariates, rules for data derivations, multiplicity control and sensitivity analyses. Missing data must not simply be ignored, because this can bias conclusions. The chosen main analysis and supplementary sensitivity analyses must therefore match the assumptions and the estimand. Deviations from the pre-planned approach must be presented transparently in the clinical study report.<\/p>\n
Biostatistics does not provide an automatic decision on the clinical relevance of a result. It quantifies the estimated treatment effect and its uncertainty, for example through confidence intervals, and tests pre-formulated hypotheses. A significance test alone does not answer whether a result is relevant for patients. For the overall evaluation, the size and direction of the effect, data quality, consistency across endpoints and subgroups, safety data and the plausibility of the underlying assumptions count.<\/p>\n
Robustness is particularly important when analyses are based on assumptions that cannot be completely verified. Sensitivity analyses examine whether the core conclusion changes significantly under traceably differing assumptions. In adaptive designs, moreover, pre-planned modifications and interim analyses must take the error probability and the estimation of the treatment effect into account. Biostatistics thus connects mathematical precision with the clinical and regulatory question.<\/p>\n
Biostatistical planning is also closely linked to the data structure. Collection time points, coding and data derivations must enable the subsequent analysis. If relevant variables are not collected or inconsistently documented, the desired treatment effect estimation can often not be established retrospectively. Quality-critical factors are therefore considered already during the design of the protocol, electronic case report form and data checks.<\/p>\n
In everyday trial practice, an early integrated biostatistical approach creates a common basis for medical, operational and regulatory decisions. Particularly critical are an unambiguous endpoint definition, the timely definition of analysis populations, a realistic sample size and completely described data flows. Authorities and auditors check whether the protocol, statistical analysis plan, database and study report match in content and whether the analysis was defined prior to knowledge of the results.<\/p>\n
Full-service CROs such as Mediconomics support the development of the statistical concept, sample size justification and statistical analysis plan as well as randomization, data management, statistical programming and the creation of tables, figures and listings. This includes aligning endpoints and estimands, planning sensitivity analyses, checking data quality and transparently presenting the analyses in the clinical study report.<\/p>\n
Is biostatistics only relevant after data collection is complete?<\/strong><\/p>\n No. The decisive statistical specifications belong in the planning phase because they determine design, endpoints, sample size, data collection and analysis. After trial start, biostatistics primarily serves the implementation and controlled interpretation of the pre-specified concept.<\/p>\n Does a p-value replace clinical assessment?<\/strong><\/p>\n No. A p-value is one element of a hypothesis test. For the evaluation of a treatment effect, the effect size, confidence interval, clinical relevance, safety profile and robustness of the analysis are additionally important.<\/p>\n Why are sensitivity analyses necessary?<\/strong><\/p>\n They show how sensitive the conclusion is to assumptions and data limitations. According to ICH E9(R1), they target the same estimand as the main analysis and investigate its robustness.<\/p>\n Biostatistics is the application of statistical principles and methods to medical and health-related questions. In clinical trials, it translates the scientific question into a robust study design, pre-specified analyses and traceable conclusions about the benefits and risks of a treatment. Task in study planning Biostatistics begins before the inclusion of the first trial participants. It […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6897","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":2,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6897\/revisions"}],"predecessor-version":[{"id":7428,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6897\/revisions\/7428"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6897"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n